Ticker	Volume	Price	Price Delta
DJIA	15,247.20	-47.27	-0.31%
S&P 500	1,644.98	-5.53	-0.34%
Nasdaq	3,445.56	-13.86	-0.40%

Ticker

Volume

Price

Price Delta

DJIA

15,247.20

-47.27

-0.31%

S&P 500

1,644.98

-5.53

-0.34%

Nasdaq

3,445.56

-13.86

-0.40%

Ticker	Volume	Price	Price Delta
STOXX 50	2,764.29	-12.49	-0.45%
FTSE 100	6,654.34	-42.45	-0.63%
DAX	8,305.32	-46.66	-0.56%

Ticker

Volume

Price

Price Delta

STOXX 50

2,764.29

-12.49

-0.45%

FTSE 100

6,654.34

-42.45

-0.63%

DAX

8,305.32

-46.66

-0.56%

Ticker	Volume	Price	Price Delta
Nikkei	14,612.50	+128.47	0.89%
Hang Seng	22,618.70	-51.01	-0.23%
S&P/ASX 200	4,983.50	-78.95	-1.56%

Ticker

Volume

Price

Price Delta

Nikkei

14,612.50

+128.47

0.89%

Hang Seng

22,618.70

-51.01

-0.23%

S&P/ASX 200

4,983.50

-78.95

-1.56%

Roche May Abandon its Bid for Illumina, SonntagsZeitung Reports

By Leigh Baldwin - 2012-04-01T11:15:14Z

Roche Holding AG (ROG), a Basel, Switzerland-based drugmaker, may drop its $6.6 billion bid for Illumina Inc. (ILMN), SonntagsZeitung reported, citing an unidentified person close to Roche’s board.

San Diego, California-based Illumina, a diagnostics company, can’t rely on Roche’s continuing participation in negotiations, the person said, adding that for Roche, Illumina is a “nice-to-have,” not a “must-have,” the Swiss newspaper reported.

To contact the reporter on this story: Leigh Baldwin in Zurich at lbaldwin3@bloomberg.net

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net

More News:

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.